GRAIL raises $325 million in private placement

GRAIL , the Menlo Park–based healthcare company focused on early cancer detection, announced a $325 million private placement from new and existing investors, including Deep Track Capital, Farallon Capital Management, Hims & Hers, and Braidwell LP.

The company plans to use the funds to advance commercialization, reimbursement efforts, and general operations. Combined with its existing cash and investments, Grail expects to be funded through 2030, excluding a previously announced $110 million investment from Samsung C&T and Samsung Electronics.

Morgan Stanley and Goldman Sachs acted as placement agents for the transaction, which is expected to close on October 21, 2025.